首页 > 市场调查报告书 > 医疗设备

医学影像诊断核子医学

市场调查报告书

商品编码

1373403

全球核子造影设备市场 - 2023-2030

Global Nuclear Imaging Equipment Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

核子造影技术通常称为核子医学影像设备，是一种高度发展的影像仪器，用于核医学领域，用于观察和评估人体内部的众多生理结构和过程。这些设备使用微量放射性物质（放射性追踪剂或放射性药物）提供内部器官、组织和生理过程的图像。

核子造影技术对于检测和监测许多疾病至关重要，例如癌症、心臟病、神经系统问题和骨骼异常。选择的设备取决于特定的临床应用和医疗保健专业人员所需的资料。这些机器由合格的放射科医生和核医技术人员使用，对于当代医疗保健至关重要。

动力学

增加研究活动

截至2023年6月，英国公司Serac Imaging Systems开发了一款便携式高解析度混合伽马光学相机，目前正在美国进行临床试验。 Seracam 影像设备试验预计将有 25 名参与者参与，持续约六个月。俄亥俄州立大学韦克斯纳医学中心是第二个开展由研究者资助的研究的地点，该研究旨在将使用Seracam 获得的伽马图像与使用当前最先进的核医学成像伽马相机捕获的图像进行比较，这些影像来自同一名患者同一天，在马来西亚吉隆坡进行测试后。

该设备使用辐射来扫描放射性同位素，然后将其提供给患者，其方式类似于 X 射线天文学中使用的卫星，后者最初由莱斯特大学创建。这揭示了身体如何运作的细节，例如是否存在任何阻塞。

技术进步

根据2023 年《欧洲核子医学和分子成像杂誌》上发表的文章，最新的PET/MRI 系统，例如具有硅光电倍增管(SiPM) 探测器和飞行时间(TOF) 功能的系统，可提供更高的灵敏度与传统设备相比。此外，合成 MRI 和指纹辨识技术等 MRI 技术的发展，加上人工智慧重建方法，在研究环境中具有很大的应用潜力。这些进步可能会缩短 MRI 获取资料所需的时间，同时仍能实现功能和解剖成像。

然而，重要的是要记住，即将推出的新一代 PET/MRI 设备将改变这种情况。这些新系统预计将有许多改进，包括使用更大磁铁和更大直径孔径的改进 MRI 系统、更宽的轴向覆盖范围，从而提高 PET 灵敏度。此外，这些新设备将配备专门开发的人工智慧软体，以利用尖端成像序列加快临床吞吐量。由此将缩短采集时间（25-30 分钟）并提高 MRI 灵敏度。

成本高

医疗机构必须对 PET 和 SPECT 扫描仪等核子造影设备进行大量前期资本投资。这个价格涵盖了成像系统本身、安装以及为设备腾出空间所需的任何基础设施改造的成本。除初始购买费用外，核成像设备还包括持续维护和营运支出。为了确保设备的准确性和可靠性，这也包括日常维护和校准。

在核子造影程序中使用放射性药物会增加整体成本，即使它们不属于设备成本的一部分。放射性药物的价格可能很高，并且根据所使用的特定示踪剂而变化。

辐射暴露问题

在核子造影操作中，使用称为放射性药物或示踪剂的放射性物质。这些物质产生电离辐射。透过电离辐射从原子中去除强键结电子具有足够的能量，可能会伤害生物组织。当放射性药物给予接受核子造影的患者时，他们会暴露在电离辐射下。

根据手术类型和所使用的特定放射性药物，适用不同的辐射暴露程度。儘管风险通常不大，但仍存在一些风险。患者可能会在整个过程中经历多次核子造影治疗，特别是如果他们有持续的医疗问题需要监测。随着时间的推移，辐射暴露可能会令人担忧，尤其是对于经常进行成像的人来说。

有关此报告的更多详细资讯 - 索取样品

Nuclear imaging technology, commonly referred to as nuclear medicine imaging equipment, is a highly developed imaging instrument used in the field of nuclear medicine to observe and evaluate numerous physiological structures and processes within the human body. These devices provide images of inside organs, tissues, and physiological processes using minute quantities of radioactive substances (radiotracers or radiopharmaceuticals).

Nuclear imaging technology is essential for the detection and monitoring of a number of illnesses, such as cancer, heart disease, neurological problems, and abnormalities of the bones. The equipment selected relies on the particular clinical application and the data that healthcare professionals need. These machines, which are used by qualified radiologists and nuclear medicine technologists, are essential to contemporary healthcare.

Dynamics

Increasing Research Activities

As of June 2023, Serac Imaging Systems, a UK-based firm, developed a portable high-resolution hybrid gamma optical camera, which is currently undergoing clinical trials in the United States. The Seracam imaging device trial is anticipated to involve 25 participants and last about six months. The Ohio State University Wexner Medical Center is the second location to start an investigator-sponsored study to compare gamma images obtained using Seracam with those captured using a current state-of-the-art gamma camera for nuclear medical imaging, from the same patient on the same day, following testing in Kuala Lumpur, Malaysia.

The device uses radiation to scan radioisotopes, which are given to the patient, in a manner similar to that used in satellites used in X-ray astronomy, which was first created by the University of Leicester. This exposes details on how the body functions, such as whether there are any blockages.

Technological Advancements

As per the article published in the European Journal of Nuclear Medicine and Molecular Imaging in 2023, the newest PET/MRI systems, such as those with silicon photomultiplier (SiPM) detectors and time of flight (TOF) capabilities, offer sensitivity levels that are higher than those of traditional devices. Additionally, MRI technology developments like synthetic MRI and fingerprinting technologies, together with artificial intelligence reconstruction approaches, have a lot of potential for use in research settings. These advancements may shorten the time it takes for an MRI to acquire data while still enabling functional and anatomical imaging.

However, it is crucial to keep in mind that the imminent introduction of a new generation of PET/MRI devices will transform the scene. These new systems are anticipated to have a number of improvements, including improved MRI systems using bigger magnets and larger diameter bores, wider axial coverage, and hence increased PET sensitivity. Additionally, these new devices will come with specialized AI software developed to speed up clinical throughput using cutting-edge imaging sequences. Shorter acquisition periods (25-30 min) and increased MRI sensitivity will follow from this.

High Cost

Healthcare facilities must make a substantial upfront capital investment in nuclear imaging equipment like PET and SPECT scanners. This price covers the cost of the imaging system itself, installation, and any infrastructure alterations required to make room for the apparatus. Nuclear imaging equipment includes ongoing maintenance and operational expenditures in addition to the initial purchase. To ensure the accuracy and dependability of the equipment, this also includes routine servicing and calibration.

The use of radiopharmaceuticals in nuclear imaging procedures raises the overall cost even if they are not a part of the equipment cost. The price of radiopharmaceuticals can be high and varies according to the particular tracer that is employed.

Radiation Exposure Concerns

During nuclear imaging operations, radioactive substances known as radiopharmaceuticals or tracers are used. These substances generate ionizing radiation. The removal of strongly bonded electrons from atoms by ionizing radiation has sufficient energy to possibly harm biological tissues. When the radiopharmaceutical is administered to patients undergoing nuclear imaging, they are exposed to ionizing radiation.

Depending on the procedure type and the particular radiopharmaceutical employed, different radiation exposure levels apply. Although the risk is normally modest, there is still some risk involved. Patients may experience many nuclear imaging treatments throughout time, particularly if they have ongoing medical issues that need to be monitored. Radiation exposure over time might be a worry, especially for people who have imaging frequently.

For more details on this report - Request for Sample

Segment Analysis

The global nuclear imaging equipment market is segmented based on product, application, end-user and region.

The PET/CT segment accounted for approximately 45.7% of the market share

As per the Article published in Stat Pearls in 2023, PET/CT (positron emission tomography) is a commonly utilized nuclear medicine imaging method used to examine the staging, therapy response, or recurrence of many malignancies. In addition to mammography, which is still the primary imaging test for identifying and screening cancer, other secondary imaging modalities include ultrasound, MRI, and, under some circumstances, PET/CT. This activity examines the use of PET/CT as an additional imaging technique for the evaluation of breast cancer patients. Furthermore, the interprofessional team's use of PET/CT in the context of breast cancer is highlighted in this activity, along with the indications, imaging method, patient preparation, and use of PET/CT.

The physiological and biochemical information offered by PET is greatly enhanced by the anatomical information provided by CT. It is possible to acquire fused pictures with the combined information on a single screen and to blend from one to the other by modifying the 922 (color) scales thanks to the 919 combining of the two modalities into PET/CT by positioning the two system gantries on a 920 common axis and with a common patient bed.

Geographical Penetration

North America segment accounted for approximately 38.9% of the market share

North America has been a dominant force in the global nuclear imaging equipment market. Nuclear imaging technology is constantly improving, resulting in more accurate and effective imaging, which has fueled market expansion. Particularly common hybrid imaging technologies are PET/CT and PET/MRI, which are used for diagnosis. For instance, in June 2023, at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), GE HealthCare plans to introduce SIGNA PET/MR AIR[i]. The business will demonstrate how its cutting-edge AIR technologies may be integrated with the SIGNA PET/MR AIR system to improve diagnostic accuracy, streamline therapy evaluation, and improve patient comfort.

The need for dependable and comprehensive imaging solutions across the patient care journey is highlighted by recent FDA approvals of innovative PET radiotracers and therapeutic methods for high-prevalence disorders like prostate cancer and Alzheimer's Disease. SIGNA PET/MR AIR incorporates distinct GE HealthCare AIR technologies that respond to the changing needs of specific patient populations. These innovations include MotionFree Brain[ii], which reduces motion-related PET picture degradation, AIR Coils, which increases and improves patient comfort, AIR Recon DL, which improves MR image quality and enables scan time reduction, and AIR Coils.

COVID-19 Impact Analysis:

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global nuclear imaging equipment market. Many optional nuclear imaging scans and other non-essential medical procedures were delayed or stopped during the early stages of the pandemic in order to lower the risk of viral transmission and save money on medical services.

This resulted in a sharp decline in the number of nuclear imaging procedures, which had financial repercussions for healthcare facilities and nuclear imaging equipment producers. In order to deal with the increase in COVID-19 cases, healthcare organizations changed their focus. Due to this, healthcare workers, resources, and attention were diverted from tasks unrelated to COVID-19, such as nuclear imaging. Infrastructure developments and investments in new imaging technology were occasionally postponed or cancelled.

Competitive Landscape

The major global players in the market include Siemens Healthcare GmbH, GE Healthcare, Philips Healthcare, Canon Medical Systems Corp, Serac Imaging Systems Ltd, Neusoft Medical Systems Co Ltd., DIGIRAD HEALTH, INC., Mediso Ltd., PerkinElmer, and MILabs B.V.

Key Developments

At Arab Health 2023 in Dubai, United Imaging, a Chinese company, and I-ONE Nuclear Medicine & Oncology Center have partnered to conduct the first research and development of the PET/MR uPMR 790 in the Gulf countries.

Why Purchase the Report?

To visualize the global nuclear imaging equipment market segmentation based on product, application, end-user and region as well as understand critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of nuclear imaging equipment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global nuclear imaging equipment market report would provide approximately 61 tables, 61 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Research Activities
  - 4.1.1.2. Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. High Cost
  - 4.1.2.2. Radiation Exposure Concerns
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Positron Emission Tomography (PET) Systems*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Positron Emission Tomography/Computed Tomography (PET/CT) Systems
7.4. Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Systems
7.5. Single Photon Emission Computed Tomography (SPECT) Systems
7.6. Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Systems

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiology
8.4. Neurology
8.5. Others

9. By End-user

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.1.2. Market Attractiveness Index, By End-user
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Imaging Centers
9.4. Academic & Research Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Siemens Healthcare GmbH*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. GE Healthcare
12.3. Philips Healthcare
12.4. Canon Medical Systems Corp
12.5. Serac Imaging Systems Ltd
12.6. Neusoft Medical Systems Co Ltd.
12.7. DIGIRAD HEALTH, INC.
12.8. Mediso Ltd.
12.9. PerkinElmer
12.10. MILabs B.V.

LIST NOT EXHAUSTIVE